• 出版社/出版日：Mordor Intelligence / 2020年4月20日
|Single User||￥467,500 (USD4,250)||▷ お問い合わせ|
|Team User||￥522,500 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥825,000 (USD7,500)||▷ お問い合わせ|
The Sustained Release Excipients market studied is anticipated to grow with a CAGR of nearly 7.1%, during the forecast period.
Certain factors that are driving the market growth include increased benefits over conventional dosage forms and antibiotic resistance.
One of the major challenges for marketers of pharmaceutical products is the compliance of the patient. When a drug needs to be administered several times a day, patients’ acceptance of the medication can decrease considerably, leaving the risk of insufficient treatment. A common solution to increase medication acceptance in this case is to formulate the drug in a dosage form that releases the active ingredient steadily over an extended period of time.
Sustained-release profiles allow tailored dosing of the active ingredient over an extended period of time up to 24 hours. Common ways to achieve such release rates are the use of film coating, a sustained release matrix or sustained-release drug-loaded granules.
Such sustained release formulations have gained considerable traction in the pharmaceutical industry, and will continue to be a major tool to improve the patients experience for existing and new drugs. It also represents an attractive opportunity for companies and formulators in particular to differentiate their potentially generic product from standard instant release versions in the market.
Key Market Trends
Oral Route of Administration Holds Significant Market Share in the Global Sustained Release Excipients Market
Among the various routes of drug delivery oral route is the most preferred route. The conventional dosage form offers a few limitations which could be resolved by modifying the existing dosage form. Sustained and controlled drug delivery system helps in the maintenance of constant plasma drug concentration and retards the release rate of drug thereby extending the duration of action.
Matrix tablet is defined as an “Oral solid dosage form in which active pharmaceutical ingredient is uniformly dispersed throughout polymeric matrices (hydrophilic or hydrophobic) which retards the drug release rate.
This approach is widely used for formulating the sustained release tablets. The mechanism involved in the drug release is either dissolution controlled or diffusion controlled.
North America Dominates the Global Sustained Release Excipients Market
North America is expected to hold a major share for the sustained release excipients market and is expected to show a similar trend over the forecast period. The US extended release excipients industry is expected to evolve significantly, along with the progress of the pharmaceutical industry, as new active pharmaceutical ingredients are developed and novel technologies are adopted (i.e., novel drug delivery systems).
Following this trend, innovative multifunctional excipients and specialty blends can be expected to arrive in the market during the forecast period. In the United States, at the macro-level, the rising global demand for pharmaceuticals has fueled the growth of drug production, and consequently, excipients consumption.
The global Sustained Release Excipients market is competitive and consists of a few major players. Companies like Allergan plc, AstraZeneca, GlaxoSmithKline plc, Mayne Pharma Group Limited, Mylan N.V., Novartis AG, Pfizer, Inc., Salix Pharmaceuticals, Sun Pharmaceutical Industries Ltd., among others, hold the substantial market share in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased benefits over conventional dosage forms
4.2.2 Antibiotic resistance
4.3 Market Restraints
4.3.1 Drug toxicity due to dose dumping
4.3.2 Need for high dose of API
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.2 By Route of Administration
5.3 By Technology
5.3.1 Targeted Delivery
5.3.3 Wurster Technique
5.4.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East and Africa
5.4.5 South America
188.8.131.52 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allergan plc
6.1.3 GlaxoSmithKline plc
6.1.4 Mayne Pharma Group Limited
6.1.5 Mylan N.V.
6.1.6 Novartis AG
6.1.7 Pfizer, Inc.
6.1.8 Salix Pharmaceuticals
6.1.9 Sun Pharmaceutical Industries Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS